BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 10976015)

  • 1. The pathophysiology of cholestasis with special reference to primary biliary cirrhosis.
    Jansen PL
    Baillieres Best Pract Res Clin Gastroenterol; 2000 Aug; 14(4):571-83. PubMed ID: 10976015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adaptive changes in hepatobiliary transporter expression in primary biliary cirrhosis.
    Zollner G; Fickert P; Silbert D; Fuchsbichler A; Marschall HU; Zatloukal K; Denk H; Trauner M
    J Hepatol; 2003 Jun; 38(6):717-27. PubMed ID: 12763363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulation of rat organic anion transporters in bile salt-induced cholestatic hepatitis: effect of ursodeoxycholate.
    Rost D; Herrmann T; Sauer P; Schmidts HL; Stieger B; Meier PJ; Stremmel W; Stiehl A
    Hepatology; 2003 Jul; 38(1):187-95. PubMed ID: 12830001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The expression levels of plasma membrane transporters in the cholestatic liver of patients undergoing biliary drainage and their association with the impairment of biliary secretory function.
    Shoda J; Kano M; Oda K; Kamiya J; Nimura Y; Suzuki H; Sugiyama Y; Miyazaki H; Todoroki T; Stengelin S; Kramer W; Matsuzaki Y; Tanaka N
    Am J Gastroenterol; 2001 Dec; 96(12):3368-78. PubMed ID: 11774951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatobiliary transporter expression in percutaneous liver biopsies of patients with cholestatic liver diseases.
    Zollner G; Fickert P; Zenz R; Fuchsbichler A; Stumptner C; Kenner L; Ferenci P; Stauber RE; Krejs GJ; Denk H; Zatloukal K; Trauner M
    Hepatology; 2001 Mar; 33(3):633-46. PubMed ID: 11230744
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited.
    Paumgartner G; Beuers U
    Hepatology; 2002 Sep; 36(3):525-31. PubMed ID: 12198643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cholestatic liver diseases: slow progress in understanding and treating slowly progressive disorders.
    Vleggaar FP; Van Ooteghem NA; Van Buuren HR; Van Berge Henegouwen GP
    Scand J Gastroenterol Suppl; 2000; (232):86-92. PubMed ID: 11232499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Upregulation of a basolateral FXR-dependent bile acid efflux transporter OSTalpha-OSTbeta in cholestasis in humans and rodents.
    Boyer JL; Trauner M; Mennone A; Soroka CJ; Cai SY; Moustafa T; Zollner G; Lee JY; Ballatori N
    Am J Physiol Gastrointest Liver Physiol; 2006 Jun; 290(6):G1124-30. PubMed ID: 16423920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of nuclear receptors in the adaptive response to bile acids and cholestasis: pathogenetic and therapeutic considerations.
    Zollner G; Marschall HU; Wagner M; Trauner M
    Mol Pharm; 2006; 3(3):231-51. PubMed ID: 16749856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bile secretory failure: recent concepts of the pathogenesis of intrahepatic cholestasis.
    Simon FR; Reichen J
    Prog Liver Dis; 1982; 7():195-206. PubMed ID: 7051146
    [No Abstract]   [Full Text] [Related]  

  • 11. Expression of hepatocyte transporters and nuclear receptors in children with early and late-stage biliary atresia.
    Chen HL; Liu YJ; Chen HL; Wu SH; Ni YH; Ho MC; Lai HS; Hsu WM; Hsu HY; Tseng HC; Jeng YM; Chang MH
    Pediatr Res; 2008 Jun; 63(6):667-73. PubMed ID: 18327154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bile salt transporters.
    Meier PJ; Stieger B
    Annu Rev Physiol; 2002; 64():635-61. PubMed ID: 11826283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cholestasis and the role of basolateral efflux pumps.
    Keppler D
    Z Gastroenterol; 2011 Jul; 49(12):1553-7. PubMed ID: 22139880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bile salts and cholestasis.
    Maillette de Buy Wenniger L; Beuers U
    Dig Liver Dis; 2010 Jun; 42(6):409-18. PubMed ID: 20434968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of maternal cholestasis and treatment with ursodeoxycholic acid on the expression of genes involved in the secretion of biliary lipids by the neonatal rat liver.
    Macias RI; Jimenez S; Serrano MA; Monte MJ; Marin JJ
    Life Sci; 2006 Aug; 79(10):1014-9. PubMed ID: 16764892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tauroursodeoxycholic acid inserts the apical conjugate export pump, Mrp2, into canalicular membranes and stimulates organic anion secretion by protein kinase C-dependent mechanisms in cholestatic rat liver.
    Beuers U; Bilzer M; Chittattu A; Kullak-Ublick GA; Keppler D; Paumgartner G; Dombrowski F
    Hepatology; 2001 May; 33(5):1206-16. PubMed ID: 11343250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Intrahepatic cholestasis].
    Adachi Y; Kamisako T
    Nihon Rinsho; 1996 Mar; 54(3):788-93. PubMed ID: 8904238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Intrahepatic cholestasis in chronic liver disease].
    Roda E; Pezzoli A; Fusaroli P; Fabbri C; Jaboli F; Marchetto S; Azzaroli F; Mazzella G
    Ann Ital Med Int; 1996 Oct; 11 Suppl 2():48S-52S. PubMed ID: 9004820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [New molecular features of cholestatic diseases of the liver].
    Méndez-Sánchez N; Chavez-Tapia NC; Uribe M
    Rev Invest Clin; 2003; 55(5):546-56. PubMed ID: 14968476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic variations of bile salt transporters as predisposing factors for drug-induced cholestasis, intrahepatic cholestasis of pregnancy and therapeutic response of viral hepatitis.
    Stieger B; Geier A
    Expert Opin Drug Metab Toxicol; 2011 Apr; 7(4):411-25. PubMed ID: 21320040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.